MONTREAL and CHARLOTTE, N.C. , Nov. 14, 2019 /PRNewswire/ --  Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that Joseph G. Oliveto , President and Chief Executive Officer, will present at the following investor conferences: The Jefferies 2019 London Healthcare Conference on

– NODE-301 topline data readout expected in mid-1H20 – – Richard Pasternak , M.D. appointed to the Company's Board of Directors – MONTREAL and CHARLOTTE, N.C. , Nov. 13, 2019 /PRNewswire/ --  Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated

  MONTREAL and CHARLOTTE, N.C. , Oct. 3, 2019 /PRNewswire/ --  Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced that the first

MONTREAL and CHARLOTTE, N.C. , Sept. 10, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced the appointment of

MONTREAL and CHARLOTTE, N.C., Aug. 29, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. today announced that members of the Milestone management team will participate in the following September investor conferences: Citi's 14th Annual Biotech Conference on Thursday, September 5, 2019 in Boston,

- FDA agrees to allow initiation of NODE-303 open-label safety study without test dose and in population consistent with ongoing studies - - NODE-301 trial upsized from 100 to 150 adjudicated PSVT events to satisfy EMA requirements; Company remains on track for topline readout in 1H20 - - Company

MONTREAL and CHARLOTTE, N.C. , Aug. 6, 2019 /PRNewswire/ --  Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced that it will host a

MONTREAL and CHARLOTTE, N.C. , May 30, 2019 /PRNewswire/ --  Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced Joseph G.

MONTREAL and CHARLOTTE, N.C. , May 21, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced the presentation of

MONTREAL and CHARLOTTE, N.C. , May 14, 2019 /PRNewswire/ --  Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced that the underwriters